72 related articles for article (PubMed ID: 30562637)
1. Methylation of gene CHFR promoter in acute leukemia cells.
Gong H; Liu W; Zhou J; Xu H
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):240-2. PubMed ID: 16201259
[TBL] [Abstract][Full Text] [Related]
2. Nuclear localization of Chfr is crucial for its checkpoint function.
Kwon YE; Kim YS; Oh YM; Seol JH
Mol Cells; 2009 Mar; 27(3):359-63. PubMed ID: 19326084
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of poly(ADP-ribose) recognition by the multizinc binding domain of checkpoint with forkhead-associated and RING Domains (CHFR).
Oberoi J; Richards MW; Crumpler S; Brown N; Blagg J; Bayliss R
J Biol Chem; 2010 Dec; 285(50):39348-58. PubMed ID: 20880844
[TBL] [Abstract][Full Text] [Related]
4. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.
Sanoff HK; Renfro LA; Poonnen P; Ambadwar P; Sargent DJ; Goldberg RM; McLeod H
PLoS One; 2014; 9(4):e94727. PubMed ID: 24727911
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
Kearney MR; Chen EY; Vaccaro GM; Strother J; Burt A; Todd K; Donovan J; Kampa-Schittenhelm KM; Lopez CD
Anticancer Res; 2019 Jan; 39(1):245-252. PubMed ID: 30591465
[TBL] [Abstract][Full Text] [Related]
6. CHFR promotes metastasis of human gastric carcinoma by activating AKT and ERK via NRF2- ROS axis.
He F; Ye B; Wu X; Pan J; Wang J; Wang X
BMC Gastroenterol; 2023 Apr; 23(1):114. PubMed ID: 37024798
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review.
Ghadiri Moghaddam F; Farajnia S; Karbalaei-Mahdi M; Monir L
Mol Biol Rep; 2022 Oct; 49(10):10013-10022. PubMed ID: 35727475
[TBL] [Abstract][Full Text] [Related]
8. Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma.
González-Borja I; Alors-Pérez E; Amat I; Alonso L; Viyuela-García C; Goñi S; Reyes JC; Ceballos-Chávez M; Hernández-García I; Sánchez-Frías ME; Santamaría E; Razquin S; Arjona-Sánchez Á; Arrazubi V; Pérez-Sanz J; Vera R; Fernández-Irigoyen J; Castaño JP; Viúdez A
Front Med (Lausanne); 2021; 8():720128. PubMed ID: 34869418
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Alterations Upstream and Downstream of p53 Signaling in Colorectal Carcinoma.
Tomicic MT; Dawood M; Efferth T
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439227
[TBL] [Abstract][Full Text] [Related]
10. Integrative omics analysis reveals effective stratification and potential prognosis markers of pan-gastrointestinal cancers.
Jiangzhou H; Zhang H; Sun R; Fahira A; Wang K; Li Z; Shi Y; Wang Z
iScience; 2021 Aug; 24(8):102824. PubMed ID: 34381964
[TBL] [Abstract][Full Text] [Related]
11. Methylation-Based Therapies for Colorectal Cancer.
Cervena K; Siskova A; Buchler T; Vodicka P; Vymetalkova V
Cells; 2020 Jun; 9(6):. PubMed ID: 32599894
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
[TBL] [Abstract][Full Text] [Related]
13. WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.
Bosch LJ; Luo Y; Lao VV; Snaebjornsson P; Trooskens G; Vlassenbroeck I; Mongera S; Tang W; Welcsh P; Herman JG; Koopman M; Nagtegaal ID; Punt CJ; van Criekinge W; Meijer GA; Monnat RJ; Carvalho B; Grady WM
Clin Cancer Res; 2016 Sep; 22(18):4612-22. PubMed ID: 27121793
[TBL] [Abstract][Full Text] [Related]
14. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.
Derks S; Cleven AH; Melotte V; Smits KM; Brandes JC; Azad N; van Criekinge W; de Bruïne AP; Herman JG; van Engeland M
Cancer Metastasis Rev; 2014 Mar; 33(1):161-71. PubMed ID: 24375389
[TBL] [Abstract][Full Text] [Related]
15. CHFR: a key checkpoint component implicated in a wide range of cancers.
Sanbhnani S; Yeong FM
Cell Mol Life Sci; 2012 May; 69(10):1669-87. PubMed ID: 22159584
[TBL] [Abstract][Full Text] [Related]
16. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
[TBL] [Abstract][Full Text] [Related]
17. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
